Published

Psilocybin for depression: Considerations for clinical trial design

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of Psychedelic Studies
Date: 2019-09-01
Source: OpenAlex
DOI: 10.1556/2054.2019.026
PubMed: Unavailable

Authors

Kelley C. O’Donnell Sarah E. Mennenga Michael P. Bogenschutz

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Receptor Pharmacology Clinical Trial Review Article Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin for depression: Considerations for clinical trial design2019-09-01

Related papers

Psychedelics for Psychiatric Disorders: More Research NeededPsychiatric News · 2020-04-13 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot StudyClinicalTrials.gov · 2026-03-18 Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin CompoundsACS Omega · 2025-09-30 Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.Expert opinion on drug safety · 2022-06-01 Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling.Therapeutic advances in drug safety · 2026-01-01 Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.Drug safety · 2025-05-01 Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.Expert opinion on drug safety · 2023-01-01